Source BioScience plc is a provider of laboratory services and products to the healthcare and clinical, life and applied sciences and biopharmaceutical industries. The Company operates through two segments: Laboratory Services and Products. The Company's Laboratory Services segment consists of the laboratory and analytical testing activities of the Group including diagnostic testing for cancer and infectious disease; deoxyribonucleic acid (DNA) sequencing and contract research activities; stability and cryostorage in addition to analytical services, and stability testing. The Company's Products segment consists of portfolio of Clinical Products, including serology products for blood and tissue banking and liquid-based cytology products for cervical cancer screening, in addition to the portfolio of Life Science Research Reagents, including complementary DNA (cDNA) clones and other biomolecular tools, and controlled environment storage equipment and related servicing and validation.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Ambulance & Emergency Services
- Sub-Industry: N/A
- Symbol: LON:SBS
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: GBX 17.81
- 200 Day Moving Avg: GBX 16.38
- 52 Week Range: GBX 14 - GBX 19
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Net Margins: 4.60%
- Return on Equity: 4.26%
- Return on Assets: 2.84%
- Average Volume: 338,357 shs.
Frequently Asked Questions for Source Bioscience PLC (LON:SBS)
What is Source Bioscience PLC's stock symbol?
Source Bioscience PLC trades on the London Stock Exchange (LON) under the ticker symbol "SBS."
Who are some of Source Bioscience PLC's key competitors?
Some companies that are related to Source Bioscience PLC include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), Valeant Pharmaceuticals Intl (VRX), NMC Health PLC (NMC), Health Net (HNT), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Patheon NV (PTHN), Catalent (CTLT), Puma Biotechnology (PBYI), WuXi PharmaTech (Cayman) (WX), Cotiviti Holdings (COTV) and Enerplus Corp (ERF).
How do I buy Source Bioscience PLC stock?
Shares of Source Bioscience PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Source Bioscience PLC's stock price today?
MarketBeat Community Rating for Source Bioscience PLC (LON SBS)MarketBeat's community ratings are surveys of what our community members think about Source Bioscience PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Source Bioscience PLC stock can currently be purchased for approximately GBX 17.50.
Consensus Ratings for Source Bioscience PLC (LON:SBS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Source Bioscience PLC (LON:SBS)
(Data available from 9/19/2015 forward)
|1/29/2016||N+1 Singer||Reiterated Rating||corporate|
Earnings History for Source Bioscience PLC (LON:SBS)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Source Bioscience PLC (LON:SBS)
Current Year EPS Consensus Estimate: $1.00 EPS
Dividend History for Source Bioscience PLC (LON:SBS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Source Bioscience PLC (LON:SBS)Insider Trades by Quarter for Source Bioscience PLC (LON:SBS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/8/2015||Ash,Dr Nick||Insider||Sell||1,454,243||GBX 17||£247,221.31|
Headline Trends for Source Bioscience PLC (LON:SBS)
Latest Headlines for Source Bioscience PLC (LON:SBS)
Source Bioscience PLC (SBS) Chart for Tuesday, September, 19, 2017